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ABSTRACT
Objective Academic pathology is facing a crisis; an 
ongoing decline in academic pathology posts, a paucity 
of academic pathologist’s in-training and unilled posts 
at a time when cellular pathology departments are 
challenged to deliver increasing numbers of molecular 
tests. The National Cancer Research Institute initiative in 
Cellular & Molecular Pathology commissioned a survey 
to assess attitudes of cellular pathology consultants 
towards research in order to understand barriers and 
identify possible solutions to improve this situation. As 
cellular pathology is encompassing an increasing number 
of diagnostic molecular tests, we also surveyed the 
current approach to and extent of training in molecular 
pathology.
Methods The survey was distributed to all UK-based 
consultant pathologists via the Pathological Society of 
Great Britain & Ireland and Royal College of Pathologist 
networks. Heads of Department were contacted 
separately to obtain igures for number of academic 
training and consultant posts.
Results 302 cellular pathologists completed the 
survey which represents approximately 21% of the total 
cellular histopathology workforce. Most respondents 
(89%) had been involved in research at some point; 
currently, 22% were undertaking research formally, and 
41% on an informal basis. Of those previously involved 
in research, 57% stopped early in their consultant 
career. The majority of substantive academic posts were 
Professors of which 60% had been in post for >20 years. 
Most respondents (84%) used molecular pathology in 
diagnostic work, independent of where they worked or 
the length of time in post. Notably, 53% of consultants 
had not received molecular pathology training, 
particularly more senior consultants and consultants in 
district general hospitals.
Conclusions The survey reveals that the academic 
workforce is skewed towards senior individuals, many of 
whom are approaching retirement, with a missing cohort 
of ’junior consultant’ academic pathologists to replace 
them. Most pathologists stop formal research activity at 
the beginning of a consultant career. While molecular 
pathology is an increasing part of a pathologist’s 
workload, the majority of consultant cellular pathologists 
have not received any formal molecular training.
INTRODUCTION
Academic cellular pathology plays a pivotal role in 
advancing medical research and patient care. The 
100 000 Genomes Project1 is a current example 
of a translational research initiative to which 
academic cellular pathology is making a substantial 
contribution; cellular pathologists morpholog-
ical and molecular understanding is vital for the 
correct interpretation of study results.2 Further-
more, cellular pathologists are the gate-keepers of 
tissue biobanks, assess the quality of tissue used 
for translational molecular research and are at the 
forefront of the implementation of digital micros-
copy platforms3 which enable pathology research 
to be shared across continents.4 It is therefore of 
grave concern that the field of academic cellular 
pathology is in continuing decline.5
Over the past 15 years, the Medical Schools 
Council6 (MSC) has documented a stable number 
of overall clinical academic posts in the UK 
(figure 1) but an ongoing decline in the number of 
academic pathology posts (figure 2). Between 2000 
and 2016, the MSC data6 show that the number 
of academic pathology consultants decreased by 
69.8%, despite the overall number of pathology 
consultants increasing by 35%. In comparison 
with other specialties, pathology experienced 
the second greatest decline in academic posts6 
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closely related specialties of oncology, radiology 
and surgery experienced only a minimal decline 
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There are approximately 103 histopathology 
departments in the UK, with a total of 1444 Histopa-
thology and Cytopathology consultants, 165 unfilled 
consultant posts and approximately 100 Universi-
ty-funded consultant posts (Royal College of Patholo-
gists (RCPath) workforce data). The 2017 MSC data 
indicate that 7% of academic pathology posts are 
unfilled.6
Of particular concern, there is a paucity of junior 
academic pathologists (who represent the next 
generation of the academic pathology workforce); 
81.5% of academic pathologists hold a senior post 
(which we have defined as Senior Lecturer/Reader 
or Professor).6 This reflects a wider general histo-
pathology recruitment problem; the 2017 histopa-
thology training recruitment round had a fill rate 
of only 71% compared with 98% in 2016.7 8 The 
top-heaviness of the academic pathology workforce 
is set to continue; between 2015 and 2016, the number 
of Professors increased by 76.2% while the number 
of Lecturers declined by 46.7% and the number 
of Readers/Senior Lecturers declined by 53.1%, 
suggesting promotion of established academics, with 
an insufficient supply of new appointments at Senior 
Lecturer level to maintain the workforce.6
The current official UK academic histopathology 
training pathway is optional; it comprises four stages 
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Figure 1 All clinical academic posts in the UK between 200 and 2016.
Figure 2 Clinical academic pathology posts. There is a sharp decline of academic pathology posts at all levels but in particular Clinical Lecturers, 
Readers and Senior Lecturers. Data for 2001 and 2002 was not available.
and extends the duration of training. First Academic Foundation 
training which provides doctors in their first 2 years of general 
physician training with 4 months of research time. Subsequently, 
doctors in their first 3 years of histopathology specialty training 
(ST1ST3) can apply for an Academic Clinical Fellowship post that 
allocates 25% of training time to research. The aim is to generate 
sufficient pilot data to apply for an MD or PhD research training 
post. Trainees, who have completed a PhD, have passed the Fellow 
of the Royal College of Pathologist (FRCPath) Part 1 exam and are 
ST3 level or above are then eligible to apply for a Clinical Lecturer 
(CL) post. This has 50% training time ring-fenced for research. At 
the end of training, trainees can apply for a Consultant position 
with or without time protected for research or a University posi-
tion with an honorary contract with the National Health Service 
(NHS; as a Reader/Senior Lecturer). It is important to highlight 
that there are different pathways for trainees into research from a 
standard trainee specialist post to obtain a MD or PhD.
Molecular pathology is a discipline of pathology which is 
focused on the identification and analysis of various molecules 
within tissues, rather than analysis solely based on morphology. 
This includes a wide variety of techniques from immunohisto-
chemistry to sequencing technologies.9 10 Over the last decade, 
opportunities for molecular pathology training have expanded 
greatly as the DNA technology field has mushroomed with so 
many advancements.10 11
The National Cancer Research Institute initiative in Cellular 
and Molecular Pathology (CM-Path)12 was launched in 2016 to 
re-energise UK academic and molecular cellular pathology and 
to maximise tissue-based research within the NHS and in clinical 
trials. The aim of the CM-Path survey that we herein report was to 
assess current attitudes of UK histopathology consultants towards 
research. As Cellular Pathology is encompassing an increasing 
number of diagnostic molecular tests,2 we also surveyed the current 
approach to and extent of training in molecular pathology.
MATERIAL AND METHODS
The need to collect more precise information about academic and 
molecular pathology (as the MSC and RCPath data provide only a 
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Figure 3 Consultants’ level of involvement in research.
general overview) was initially addressed in a survey written by Dr 
Bridget Wilkins in 2015 that collected detailed information from 
all the major UK academic pathology centres.13 The present survey 
was designed to capture further information, focusing on whether 
consultants had ever been involved in research, if they are currently 
involved in research and whether they are doing so formally (with 
allocated paid academic sessions) or informally. The survey also 
asked streamlined questions regarding attitudes towards the 
Research Excellence Framework (online supplementary data 1). 
The survey asked for the contact details of the respondents Head 
of Department. We emailed Heads of Department separately to 
obtain figures for the number of academic training and consultant 
posts within each Department. The second section of the survey 
asked about training in molecular pathology.
We did not give a specific definition of academic pathology or 
molecular pathology.
The survey was distributed to all UK-based consultant pathol-
ogists via the Pathological Society of Great Britain & Ireland and 
RCPath email networks. It was distributed over a 4-month period 
with completion of March 2017. The complete text of the survey 
can be found in online supplementary file 1.
Statistical analysis was performed via the Statistical Package 
for the Social Sciences (SPSS V.20.0, Chicago, IL, USA) and 
Excel.
Patient and public involvement
This was a questionnaire which was only distributed to Histopa-
thology Consultants. There was no patient involvement in this 
survey.
RESULTS
Academic pathology
A total of 347 consultants completed the survey, of which 302 
were cellular pathologists (representing 21% of the total UK 
cellular pathology consultant workforce.) Of these, 88% were 
histopathologists, 7% neuropathologists, 2% oral and maxil-
lofacial pathologists (not represented by the MSC data), 1.5% 
paediatric pathologists, 1% cytopathologists and 0.5% forensic 
pathologists.
Involvement in research
The majority of respondents (89%) had been involved in research 
at some point (figure 3). The majority of this group were still 
involved in research on an informal basis (41%), with a further 
22% formally undertaking research and 26% who had previ-
ously been involved in research but were no longer involved. 
11% of respondents were never involved in research.
Length of time as a consultant
The survey asked how long each respondent had been working as 
a consultant: there were 302 responses. The highest percentage 
was the group who had been working for over 20 years (36%) 
with the remainder of the responses subdivided as follows: 
1519 years (12%), 1014 years (18%), 24 years (22%), 59 
years (7%) and 01 year (1%). In the subgroup of Consultants 
that were never involved in research, the responses subdivided 
as follows: 1519 and over 20 years (33%), 1014 years (12%), 
24 years (15%), 59 years (33%) and 01 year (12%)
Current work context
The majority of consultants were working in a teaching hospital 
(227); of the remainder, 73 were working in a district general 
hospital, 76 at a University and two in industry (of note, for 
this question, multiple answers were permitted.) In the subgroup 
of Consultants that were never involved in research, 58% were 
working in a district hospital and 42% in a teaching hospital.
Higher research degree
Just over a third of consultants (39%) held a higher degree 
(PhD or MD); the majority of these consultants (67%) had 
been a consultant for 10 years or more (figure 4). The majority 
(85%) of consultants with a higher degree were still involved 
in research either formally (37%) or informally (48%). Of all 
consultants formally involved in research, 64% had a higher 
degree and of those informally involved in research, 45% had a 
higher degree. The informally involved in research consultant 
group is a hidden academic workforce which has the potential to 
strengthen and expand the pathology research community; the 
main barriers this group identified to becoming more formally 
involved in research were lack of time, resources, funding, 
departmental support and training. One suggestion from this 
group to improve the situation was to increase the availability of 
funded research programmed activities (PAs) within consultant 
job plans.
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Figure 4 The number of years that Consultants with a higher degree had been practising as a Consultant.
Figure 5 The percentage of consultants that stopped doing research at various times in their careers.
Academic appointments
Overall, 59 consultants held a substantive academic position: 
51% were Professors, 14% Readers, 30% Senior Lecturers and 
5% Lecturers/CLs. From emailing Heads of Departments, we 
obtained the following UK-level data: there are currently 22 
National Institute of Health Research (NIHR)-funded Academic 
Clinical Fellow (ACF) posts, 11 NIHR-funded Academic 
CL posts, 36 Senior Lecturers, 3 Readers and 43 Professors. 
Although the academic grade of Reader is not available in all 
Universities, the low number is concerning, as Readers are often 
promoted to Professor. Barts and the Royal London, Liverpool, 
Edinburgh and Leeds had higher than average cellular pathology 
clinical academic positions.
Academic appointment and length of time working as a consultant
The majority (60%) of Professors had been working for more 
than 20 years, 20% between 15 and 19 years and 20% between 
10 and 14 years, indicating that a significant proportion of 
Professors will be approaching retirement in the next decade. 
Approximately a third (37.5%) of Readers had been a Consultant 
for 59 years, whereas the rest had worked as a Consultant for 
at least 10 years. Of the Senior Lecturers, 17% had worked 01 
year as a consultant, 11% 24 years, 22% 59 years, 28% 1014 
years, 5% 1519 years and 17% over 20 years.
When consultants stopped their involvement with research
Of the consultants who had previously been involved in research, 
57% stopped research either on becoming a consultant or during 
their early consultant career (figure 5).
Molecular pathology
The molecular pathology questions were completed by 274 
consultants.
Use of molecular pathology in diagnosis
The majority of respondents (84%) stated that they use molec-
ular pathology in their diagnostic work, with half of these stating 
that they use molecular pathology a lot. Only 8% did not use 
molecular pathology for diagnosis. Responses were similar 
403Brockmoeller S, et al. J Clin Pathol 2019;72:399–405. doi:10.1136/jclinpath-2018-205568
Original article
across consultants working in both teaching hospitals (39% 
using it a lot) and district general hospitals (37% using it a lot) 
and across the different categories of length of time consultants 
had been in post (from 0 to 1 year to 20+years), indicating that 
similar proportions of consultants at all levels working in both 
major types of hospital setting are using molecular pathology 
diagnostically. Of the consultants that have never been involved 
in research, 24% use molecular pathology a lot, in comparison 
with 43% of consultants that are formally involved in research.
Furthermore, 46% of consultants anticipated that molecular 
pathology will become increasingly important in the near 
future and a further 45% anticipated that it will become essen-
tial (total 91%). These attitudes were similar among consul-
tants working at district general hospitals (75%) and teaching 
hospitals (84%). In the subgroup of consultants that were never 
involved in research, 53% anticipated that molecular pathology 
will become increasingly important in the near future and a 
further 28% anticipated that it will become essential (total 
86%). 15% of responders stated that it is not important as I 
am reaching the end of my career. In the group of consultants 
which are formally involved in research, 25% anticipated that 
molecular pathology will become increasingly important in the 
near future and a further 57% anticipated that it will become 
essential (total 82%). 1.5% of responders stated that it is not 
important as I am reaching the end of my career.
Almost a fifth (19%) of consultants stated that they are 
involved in the delivery of molecular pathology services. The 
majority of these consultants (96%) were currently involved in 
research either formally (43%) or informally (53%) and almost 
all were working in a teaching hospital (96%).
Training in molecular pathology
Of concern, 53% of consultants had not received any molec-
ular pathology training; 39% had been trained informally (the 
majority of which is local support interpreting reports) and 9% 
had undergone some formal training. Importantly, senior consul-
tants were less likely to have received any molecular pathology 
training despite molecular pathology being used diagnostically 
by consultants at all levels. Furthermore, despite molecular 
pathology being used diagnostically by similar proportions of 
consultants working in teaching hospitals and district general 
hospitals, consultants working in district general hospitals 
were less likely to have received any molecular training (63% 
compared with 42% of consultants working in teaching hospi-
tals) and were less likely to have received any formal training 
(3% compared with 9% of consultants working in teaching 
hospitals). The majority (79%) of consultants who had received 
formal training in molecular pathology were currently involved 
in research (either formally or informally), indicating the overlap 
between molecular and academic pathology.
Consultants stated that most of their molecular pathology 
training stemmed from interacting with the scientists that 
produce molecular pathology reports through the following: 
establishing local molecular services; research activities; learning 
on the job and self-directed reading and attending courses. 
Consultants identified a number of key training topics, including 
genomics, bioinformatics, biomarker validation and digital 
pathology. Ideally, they felt that training should be clinically 
applicable, specialty specific, provided within study leave time 
and budget and delivered as an initial training session followed 
by updates. A minority of consultants felt that molecular training 
was inappropriate for them, citing approaching retirement and 
an inappropriate division of labour/duplicating skill sets.
The perceived barriers to the use of molecular pathology were 
a lack of funding, too many competing commitments, a lack of 
specialty-specific training, a lack of clear guidance, the increasing 
rate of use of new molecular techniques and the perception of 
molecular pathology as a distinct entity.
DISCUSSION
Given the current parlous state of academic cellular pathology 
and the importance of molecular pathology in mainstream diag-
nostic pathology, this survey was designed to assess UK consul-
tant cellular pathologists attitudes to these areas, in particular 
focusing on barriers to research and training in molecular 
pathology, so that the results of the survey might direct solutions 
to address these issues.
The survey data should be interpreted with the caveat that 
only 21% of the total consultant cellular pathology workforce 
completed the survey. The consultant cellular pathology work-
force is defined as consultant cellular pathologists who are regis-
tered with the RCPath and working in the UK. Perhaps due to 
distribution of the survey via the Pathological Society, which is 
a highly research-focused society for pathologists, 70% of the 
academic cellular pathology consultant workforce completed the 
survey. This means that our data may represent a more favour-
able picture of the attitudes of consultants towards academic 
pathology than is present in the total UK pathology workforce. 
However, it is unlikely to present a more favourable view of 
attitudes towards molecular pathology as this part of our survey 
revealed similar attitudes among all respondents.
Self-identification and differences in interpretation of the 
terms of molecular pathology and academic pathology are limita-
tions of the survey. However, we made every effort to confirm 
the number of substantive academic consultants by contacting 
the relevant Heads of Department.
A further limitation of the survey was that data on gender were 
not collected. This is unfortunate, as independent data indicate14 
that there are more male than female clinical academic pathol-
ogists, particularly at more senior, Professorial positions. In our 
data, we saw the sharpest decline in individuals involvement 
in research (despite having a higher degree) at the beginning 
of, or in the early years of, their consultant careers (figure 5). 
Data from other specialties suggest that the attrition of academic 
medicine workforce numbers at the point of transition to consul-
tant is greater for females compared with males.15 A further, 
wider question is how clinic academic careers can be made more 
attractive for not just women but all consultant pathologists 
with caring responsibilities, for example flexible working hours, 
support with childcare arrangements especially during confer-
ences16 17 and availability of academic funds to support research 
during career breaks.18 These issues are closely linked to the 
work of the Athena Swan Charter. These data raise the question 
of whether programme to provide payment for research-specific 
clinical sessions for academically trained cellular pathologists 
might effectively reduce the number of consultants stopping 
research at this point of their careers.19
The data collected from Heads of Departments confirm that 
there is a small number of UK academic cellular pathologists. 
These data are in keeping with the MSC data which have shown 
a marked decline in academic pathologists over the last decade. 
The majority (67%) of consultants who have a higher degree 
have been a consultant for 10 years or more and the academic 
post after retirement have not been replaced like-for-like. There 
is also an indication of a paucity of pathology trainees currently 
undertaking higher degrees. Of the few that do, many stop 
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their formal involvement in research early in their consultant 
career due to a lack of dedicated time for research, a lack of 
senior academic University posts, the high requirements for 
transition to Senior Lecturer and very high requirements to 
gain a substantial Clinical Research Fellowship such as a Clin-
ican Scientist Fellowship. This missing cohort of junior consul-
tant academic pathologists at Senior Lecturer level represents 
one of the key findings emerging from this survey. Universities 
should be persuaded that maintaining a research active cohort 
of Senior Lecturers in academic cellular pathology is important 
for maintaining future research efforts both in Pathology and in 
wider research areas. The skewing of the academic workforce 
towards more senior individuals, a large proportion of whom 
are approaching retirement, will mean that there is an imminent 
decline in mentors and role models to inspire and guide the next 
generation of cellular pathology academics.
The survey has also highlighted the need to nurture the next 
generation of academic cellular pathologists. A possible solution 
to improve the total number of academic pathologists could be 
to increase early visibility through promotion of pathology and 
academic medicine at medical school and to increase the number 
of academic foundation histopathology posts. This should 
continue by supporting a higher number of cellular pathology 
trainees to undertake research including increased numbers of 
ACFs, funded PhD research fellowships and CL positions. The 
Pathological Society of Great Britain and Ireland is championing 
academic pathology throughout this academic training pathway. 
Members of CM-Path have met with representatives of the 
RCPath to develop proposals for revising the existing optional 
research module within the Histopathology Curriculum.
Of particular interest, the survey reveals that a large propor-
tion of consultant pathologists are undertaking research infor-
mally outwith their job plans; many would like to increase 
their research activities but feel they require dedicated research 
time to do so. This group represents a trained and enthusiastic 
hidden academic workforce, which could contribute more to 
pathology research, if better supported. A proportion of senior 
lecturers in our survey have honorary contracts with a univer-
sity but no paid sessional commitment in job plans for research. 
It is important to highlight the goodwill of these Consultants 
who are supporting academic pathology within their own time 
and to consider the costs to the NHS and academic pathology 
if this goodwill was lost through, for example, lack of support 
and increasing competing work pressures. This would have wide 
implications, for example, for the collection of tissue samples, 
trials, education of technical staff and trainees. One possible 
approach to address this would be by providing dedicated 
funded research sessions, such as through clinical trials funding 
or major programmatic research funding and for pathologists 
to insist on funded research PAs when agreeing to contribute 
pathological expertise to research programme and trials. Another 
possibility could be offering re-training and research exposure to 
Histopathology Consultants that were once research active. It 
is extremely reassuring to note that the MRC and NIHR have 
recently launched a funded scheme supporting NHS consultants 
with a PhD or MD (or equivalent higher research degree) to 
collaborate with biomedical researchers working in centres of 
research excellence; histopathologists who are eligible should be 
encouraged to apply.20
The molecular pathology section of the survey has revealed 
that the majority of consultant cellular pathologists are using 
molecular pathology in their diagnostic work yet are doing so 
without any formal training. The survey indicates that fewer 
senior consultants and cellular pathologists working in district 
general hospitals have received training in molecular pathology 
compared with their more junior colleagues and those working 
in teaching hospitals, despite consultant pathologists of all grades 
and hospital settings using molecular pathology diagnostically to 
a similar degree. Centralisation of NHS services over the past few 
decades has meant that there is now a greater concentration of 
histopathologists working in teaching hospitals; however, there 
should not be such inequity in molecular pathology training. 
The RCPath has formally introduced molecular pathology into 
the current histopathology training curriculum so that histo-
pathology trainees are receiving molecular pathology training 
and there remains scope to expand and improve this further2 ; 
however, training for the existing consultant workforce has not 
been formalised.
A number of courses such as the Health Education England 
Master Degree or Postgraduate certificate in Genomic Medicine 
have been funded to address molecular pathology training and 
to develop a workforce of morphomolecular pathologists.2 
These courses have not been histopathology-specific (they 
are for doctors from all specialties and biomedical scientists); 
a dedicated histopathology-specific course could specifically 
address the clinical issues related to molecular pathology that 
histopathologists are facing. To this extent, the British Division 
of the International Academy of Pathology (BPIAP) and the 
CM-Path have organised several molecular pathology confer-
ences/study days with the aim to update the workforce. Consul-
tants need the encouragement, time and funding to attend 
such courses. The UKs patchy and self-directed approach to 
molecular pathology training of consultants is in contrast to 
the formalised post-residency fellowship programme offered in 
the US.
While a minority of respondents felt that molecular training 
was inappropriate for them, citing approaching retirement and 
an inappropriate division of labour/duplicating skill sets, and 
while an increasing number of molecular tests are becoming 
automated,21 there is still and always will be a requirement 
for cellular pathologists to understand the molecular tests that 
they request and to interpret the results in the context of the 
sample quality and clinical information.10 Training will need to 
be ongoing throughout the career of a consultant histopathol-
ogist as molecular tests evolve and increase with the advance-
ment of molecular technologies. Such ongoing training may not 
need to be formalised and could take the form of self-directed 
experiential learning and continuing professional development, 
with competency assessed and monitored by quality assurance 
schemes such as the NEQAS scheme for programmed death-li-
gand 1 (PD-L1) reporting.11
It is noteworthy that consultants who are involved currently 
in research, either formally or informally, are more likely to be 
involved in the delivery of molecular pathology services and 
to have received formal molecular pathology training. Their 
attitude towards molecular medicine is the strongest between 
all subgroups as more than half of this group stated that it is 
essential. This reiterates the importance of academic cellular 
pathology as pathology diagnostics become increasingly morph-
omolecular. Research-active consultant cellular pathologists 
have the potential to be an important resource in disseminating 
molecular knowledge to colleagues.
It is hoped that all of the aforementioned actions will start 
to address the issues facing academic and molecular cellular 
pathology. We plan to monitor progress with follow-up surveys 
as these initiatives are implemented and to use qualitative 
methods to explore attitudes, challenges and possible solutions 
in greater depth.
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Take home messages
 Ź The survey reveals that academic pathology is facing a crisis 
as the workforce is skewed towards senior individuals, many 
of whom are approaching retirement and a missing cohort of 
‘junior consultant’ academic pathologists to replace them.
 Ź Most pathologists stop formal research activity at the 
beginning of a consultant career.
 Ź While molecular pathology is an increasing part of a 
pathologist’s workload, the majority of consultant cellular 
pathologists have not received any formal molecular training.
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